Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4145248 | 0.87 | GRIN2B (0.51) | HTR1DOPRK1GRIN2BFAAHHRH3 | |
| SCHEMBL8676741 | 0.87 | OPRK1 (0.53) | FYNHTR1DOPRK1GRIN2BFAAH | |
| SCHEMBL4132535 | 0.86 | OPRM1 (0.44) | FYNHTR1DOPRK1GRIN2BFAAH | |
| SCHEMBL4136629 | 0.86 | OPRM1 (0.44) | FYNHTR1DOPRK1GRIN2BFAAH | |
| SCHEMBL4148545 | 0.86 | HTR1A (0.44) | HTR1DGRIN2BFAAHHRH3HTR1A | |
| SCHEMBL4141143 | 0.86 | OPRM1 (0.44) | FYNHTR1DOPRK1GRIN2BFAAH | |
| SCHEMBL4135876 | 0.85 | GRIN2B (0.41) | FYNHTR1DGRIN2BFAAHHRH3 | |
| SCHEMBL4143276 | 0.84 | CYP11B2 (0.42) | HTR1DGRIN2BHRH3HTR1AHTR7 | |
| SCHEMBL4136102 | 0.84 | FAAH (0.44) | GRIN2BFAAH | |
| SCHEMBL4132414 | 0.83 | HRH3 (0.45) | HTR1DFAAHHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | FYN 2351/4885HTR1D 25/4885OPRK1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.